{"id":14351,"date":"2019-10-25T06:42:03","date_gmt":"2019-10-25T10:42:03","guid":{"rendered":"https:\/\/medicarereport.org\/?p=14351"},"modified":"2019-10-25T06:42:03","modified_gmt":"2019-10-25T10:42:03","slug":"an-alzheimers-patient-on-what-was-lost-when-biogen-shut-down-its-trial-and-what-may-be-gained-again","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=14351","title":{"rendered":"An Alzheimer\u2019s patient on what was lost when Biogen shut down its trial, and what may be gained again"},"content":{"rendered":"<p>(By Damian Garde and Adam Feuerstein for ST<em>A<\/em>T)<\/p>\n<p>Biogen\u2019s decision to revisit a once-failed treatment for Alzheimer\u2019s disease came as a shock to scientists, doctors, and investors alike. For Debby Rosenkrantz, the surprise came with a bit of hope.\u00a0 Continue reading article <a href=\"https:\/\/www.statnews.com\/2019\/10\/25\/alzheimers-patient-biogen-clinical-trial-aducanumab\/\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Damian Garde and Adam Feuerstein for STAT) Biogen\u2019s decision to revisit a once-failed treatment for Alzheimer\u2019s disease came as<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,15],"tags":[],"class_list":["post-14351","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14351"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14351\/revisions"}],"predecessor-version":[{"id":14352,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/14351\/revisions\/14352"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14351"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14351"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}